Cost utility of prostate cancer chemoprevention with dutasteride in men with an elevated prostate specific antigen

Cancer Prevention Research

Volumn 4, Issue 2, 2011, Pages 277-283

  Svatek, Robert S ^a   Lotan, Yair ^b  

^a UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DUTASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN;

ADULT; ANTIGEN SPECIFICITY; ARTICLE; CANCER PREVENTION; CANCER SURVIVAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE SURVEILLANCE; HEALTH STATUS; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY ADJUSTED LIFE YEAR;

5-ALPHA REDUCTASE INHIBITORS; AZASTEROIDS; COST-BENEFIT ANALYSIS; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79551712770     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-10-0200     Document Type: Article

References (24)

1. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24. (Pubitemid 36859473)
2. Thomas LN, Lazier CB, Gupta R, Norman RW, Troyer DA, O'Brien SP, Rittmaster RS. Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer. Prostate 2005;63:231-9. (Pubitemid 40571057)
3. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010;362:1192-202.
4. Svatek RS, Lee JJ, Roehrborn CG, Lippman SM, Lotan Y. The cost of prostate cancer chemoprevention: a decision analysis model. Cancer Epidemiol Biomarkers Prev 2006;15:1485-9. (Pubitemid 44299320)
5. Svatek RS, Lee JJ, Roehrborn CG, Lippman SM, Lotan Y. Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis. Cancer 2008;112:1058-65. (Pubitemid 351304590)
6. Surveillance, Epidemiology, and End-Results. National Cancer Institute, 2007[Accessed October 6, 2010, 2010]. Available from: www.seer.cancer.gov.
7. Roehrborn CG, Siami P, Barkin J, Damiao R, Major-Walker K, Nandy I, Morrill BB, Gagnier RP, Montorsi F. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010;57:123-31.
8. Gold MR SJ, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
9. Siegel JE, Torrance GW, Russell LB, Luce BR, Weinstein MC, Gold MR. Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine. Pharmacoeconomics 1997;11:159-68.
10. Stewart ST, Lenert L, Bhatnagar V, Kaplan RM. Utilities for prostate cancer health states in men aged 60 and older. Med Care 2005;43:347-55. (Pubitemid 40515624)
11. White CC, Koplan JP, Orenstein WA. Benefits, risks and costs of immunization for measles, mumps and rubella. Am J Public Health 1985;75:739-44. (Pubitemid 15010474)
12. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90:766-71. (Pubitemid 28259189)
13. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. J Am Med Assoc 1999;281:1591-7. (Pubitemid 29211767)
14. Krahn M, Ritvo P, Irvine J, Tomlinson G, Bremner KE, Bezjak A, Trachtenberg J, Naglie G. Patient and community preferences for outcomes in prostate cancer: implications for clinical policy. Med Care 200341:153-64.
15. Mittmann N, Trakas K, Risebrough N, Liu BA. Utility scores for chronic conditions in a community-dwelling population. Pharmacoeconomics 1999;15:369-76. (Pubitemid 29190028)
16. Zeliadt SB, Etzioni RD, Penson DF, Thompson IM, Ramsey SD. Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer. Am J Med 2005;118:850-7. (Pubitemid 41097462)
17. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 2004;172:910-4. (Pubitemid 39096421)
18. Helfand BT, Fought AJ, Loeb S, Meeks JJ, Kan D, Catalona WJ. Genetic prostate cancer risk assessment: common variants in 9 genomic regions are associated with cumulative risk. J Urol 2010;184:501-5.
19. Nahin RL, Barnes PM, Stussman BJ, Bloom B. Costs of complementary and alternative medicine (CAM) and frequency of visits to CAM practitioners: United States, 2007. Natl Health Stat Report 2009;1-14.
20. Bayoumi AM, Brown AD, Garber AM. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. J Natl Cancer Inst 2000;92:1731-9.
21. Piper NY, Kusada L, Lance R, Foley J, Moul J, Seay T. Adenocarcinoma of the prostate: an expensive way to die. Prostate Cancer Prostatic Dis 2002;5:164-6. (Pubitemid 34777902)
22. Benoit RM, Gronberg H, Naslund MJ. A quantitative analysis of the costs and benefits of prostate cancer screening. Prostate Cancer Prostatic Dis 2001;4:138-45. (Pubitemid 32923226)
23. Bolenz C, Gupta A, Hotze T, Ho R, Cadeddu JA, Roehrborn CG, Lotan Y. Cost comparison of robotic, laparoscopic, and open radical prostatectomy for prostate cancer. Eur Urol 2010;57:453-8.
24. Stanford JL, Feng Z, Hamilton AS, Gilliland FD, Stephenson RA, Eley JW, Albertsen PC, Harlan LC, Potosky AL. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. J Am Med Assoc 2000;283:354-60. (Pubitemid 30051753)